In brief: Rockeby, C3, Heartware

By Staff Writers
Friday, 04 March, 2005

Rockeby Biomed Limited (ASX:RBY) is poised to launch its Candia5 candidiasis diagnostic in Europe, having received ISO certification and CE Mark approval for the product.

Clinical Cell Culture (C3, ASX:CCE) has notched up the first commercial sale of spray-on-skin technology, ReCell, to its Japanese distributor and the announced the first use of ReCell in Japan. C3 Chief Executive Officer Troels Jordansen said the company had invoiced over AUD$400,000 in the first quarter of the calendar year in Japan.

HeartWare (ASX:HTW) has appointed corporate lawyer David McIntyre as chief financial officer and company secretary.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd